Antimicrobial resistance of nosocomial Enterococcus spp. isolated from blood culture in patients with hematological malignancies | CMAC

Antimicrobial resistance of nosocomial Enterococcus spp. isolated from blood culture in patients with hematological malignancies

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(2):142-149

​ Klyasova G.A., Fyodorova A.V., Frolova I.N., Khrulnova S.A., Vetokhina A.V., Kaporskaya T.S., Skorobogatova E.V., Molchanova I.V., Pospelova T.I., Krainova L.E., Shushurina S.E., Khoreva O.E., Zvyozdkina N.N, Kutsevalova O.Yu.
10.36488/cmac.2018.2.142-149
bacteremia hematological malignancies VRE Enterococcus faecium antimicrobial resistance linezolid resistance
Section
Antimicrobial Resistance
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(2):142-149

Objective.

To evaluate antimicrobial susceptibility of Enterococcus spp. isolated from blood culture in patients with hematological malignancies.

Materials and Methods.

Antimicrobial susceptibility of 427 Enterococcus spp. collected from 10 hospitals in 8 cities of Russia in 2002-2016 as part of the multicenter study was tested by the broth microdilution method [CLSI 2015].

Results.

Among bloodstream pathogens there was a prevalence of E. faecium (78.2%), followed by E. faecalis (19.7%) and other Enterococcus spp. (2.1%). A total of 50 (15%) vancomycin-resistant E. faecium (Vancomycin-resistant Enterococcus – VRE) was detected, of them 33 (66%) were harboring vanA gene, 17 (34%) – vanB gene. In 2012 one linezolid resistant E. faecium (MIC = 16 µg/mL) was detected. Linezolid-resistant E. faecium contained the G2576T 23S rRNA mutation. All VRE faecium including the one linezolid-resistant isolate were susceptible to daptomycin. All E. faecium were susceptible to tigecycline, 78.7% – to chloramphenicol, 74.9% – to tetracycline. Proportion of E. faecium with high level resistance to gentamicin was 85%, to streptomycin – 60%, to both aminoglycosides – 45%. All E. faecalis were susceptible to linezolid, teicoplanin and tigecycline; 97.6% – to ampicillin. One isolate of E. faecalis (1.2%) with intermediate susceptibility to vancomycin (MIC = 16 µg/mL) harboring vanD gene and one isolate of E. gallinarum resistant to vancomycin, carrying vanC1 and vanB genes were detected.

Conclusions.

Isolates of E. faecalis had more favorable profile of antimicrobial susceptibility comparing to E. faecium. A total of 15% E. faecium were vancomycin resistant and one of them had resistance to linezolid. In this study one E. faecalis and one E. gallinarum isolates were non-susceptible to vancomycin.

Galina A. Klyasova

National Medical Research Center of Hematology, Moscow, Russia

Anastasiya V. Fyodorova

National Medical Research Center of Hematology, Moscow, Russia

Frolova I.N.

National Medical Research Center of Hematology, Moscow, Russia

Svetlana A. Khrulnova

National Medical Research Center of Hematology, Moscow, Russia

Vetokhina A.V.

Irkutsk Regional Clinical Hospital, Irkutsk, Russia

Kaporskaya T.S.

Irkutsk Regional Clinical Hospital, Irkutsk, Russia

Skorobogatova E.V.

Russian Children’s Clinical Hospital, Moscow, Russia

Molchanova I.V.

Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russia

Pospelova T.I.

City Clinical Hospital #2, Novosibirsk, Russia

Krainova L.E.

Novosibirsk Regional Clinical Hospital, Novosibirsk, Russia

Shushurina S.E.

Samara Regional Clinical Hospital named after V.D. Seredavin, Samara, Russia

Khoreva O.E.

Surgut District Clinical Hospital, Surgut, Russia

Zvyozdkina N.N

Regional Clinical Hospital, Barnaul, Russia

Kutsevalova O.Yu.

Rostov Research Institute of Oncology, Rostov-on-Don, Russia

  • 1. Okhmat V.A., Klyasova G.A., Parovichnikova E.N., et al. Spectrum and epidemiology of infection complications in patients with acute myeloid leukemia during induction and consolidation chemotherapy. Gematologiya i transfusiologiya. 2017;62(1):9-15. Russian.
  • 2. Klyasova G.A., Speranskaya L.L., Mironova A.V., et al. The pathogens causing sepsis in immunocompromized patients: structure and problems of antibiotic resistancE. Results of a multi-center cooperative study. Gematologiya i transfusiologiya. 2007;1:1-8. Russian.
  • 3. Klyasova G.A. Infections in patients with hematological malignancies: clinical features, diagnosis and treatment. PhD Thesis. Moscow; 2009. Russian.
  • 4. Mikulska M., Viscoli C., Orasch C., et al. Fourth European Conference on Infections in Leukemia Group (ECIL-4), a joint venture of EBMT, EORTC, ICHS, ELN and ESGICH/ESCMID. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2013;68:321-331.
  • 5. Suntharam N., Lankford M.G., Trick W.E., Peterson L.R., Noskin G.A. Risk factors for acquisition of vancomycin-resistant enterococci among hematology-oncology patients. Diagnostic Microb Infect Dis. 2002;43:183-188.
  • 6. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. CLSI document M100-S25. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.
  • 7. Dutka-Malen S., Evers S., Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol. 1995;33:24-27.
  • 8. Bonora M.G., Ligozzi M., Luzzani A., et al. Emergence of linezolid resistance in Enterococcus faecium not dependent on linezolid treatment. Eur J Clin Microbiol Infect Dis. 2006;25:197-198.
  • 9. Mendes R.E., Deshpande L.M., Farrell D.J., et al. Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J Antimicrob Chemother. 2010;65(11):2329-2335.
  • 10. Kehrenberg C., Schwarz S. Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob Agents Chemother. 2006;50:1156-1163.
  • 11. Inkster T., Coia J., Meunier D., et al. First outbreak of colonization by linezolid- and glycopeptide-resistant Enterococcus faecium harbouring the cfr gene in a UK nephrology unit. J Hosp Infect. 2017;97(4):397402.
  • 12. Tan C.-K., Lai C.-C., Wang J.-Y., et al. Bacteremia caused by nonfaecalis and non-faecium enterococcus species at a medical center in Taiwan 2000 to 2008. J Infect. 2010;61(1):34-43.
  • 13. European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases Stockholm: ECDC; 2017. Available at: https://ecdc.europa.eu/en/surveillance-atlas-infectious-diseases. Accessed: 21.06.2018.
  • 14. Jones R.N., Marshall S.A., Pfaller M.A., et al. Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group. Diagn Microbiol Infect Dis. 1997;2:95-102.
  • 15. Sidorenko S.V., Rezvan S.P., Grudinina S.A., Krotova L.A., Sterkhova G.V. Multicenter trial of enterococcus antibiotic susceptibility. Antibiotiki i himioterapija. 1998;9:9-17. Russian.
  • 16. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2015. Annual report of the European Antimicrobial Resistance Surveillance Network (EARSNet). Stockholm: ECDC; 2016. Available at: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/antimicrobial-resistanceeurope-2015.pdf. Accessed: 21.06.2018.
  • 17. Weiner L.M., Webb A.K., Limbago B., et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol. 2016;37:1288-1301.
  • 18. LeClercq R., Derlot E., Duval J., Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988;319:157-161.
  • 19. Uttley A.H., Collins C.H., Naidoo J., George R.C. Vancomycinresistant enterococci. Lancet. 1988;i57-58.
  • 20. Kliasova G., Sidorenko S., Speranskaja L., Fedorova A.V. Detection of vanb2 in Enterococcus gallinarum in Moscow, Russia. Intern J Antimicrob Agents. 2004;24(2):131.366/79P.
  • 21. Fedorova A.V., Cherkashin E., Kliasova G., et al. First detection of vancomycin-resistant enterococci in Russia: genetic background. Clin Microbiol Infect. 2006;12(S4):131;P1819.
  • 22. Bagirova N.S., Dmitrieva N.V. Enterococcal bacteraemia in patients with haematological malignancies. Clin Microbiol Infect. 2006;12(S4):8;P699.
  • 23. Lyubimova A.V., Zueva L.P., Kolodgieva V.V., Goncharov A.E. Prevalence of Colonization of Neonatal Intensive Care Unit Patients with Vancomycin-Resistant Enterococci. Jepidemiologija i vakcinoprofilaktika. 2011;4(59):27-30. Russian.
  • 24. Brilliantova A.N., Kliasova G.A., Mironova A.V., et al. Spread of vancomycin-resistant Enterococcus faecium in two haematological centres in Russia. Intern J Antimicrob Agents. 2010;35(2):177-181.
  • 25. Cattoir V., Leclercq R. Twenty-five of shared life with vancomycinresistant enterococci: is it time to divorce? J Antimicrob Chemother. 2013;68:731-742.
  • 26. Boyd D.A., Willey B.M., Fawcett D., Gillani N., Mulvey M.R. Molecular characterization of Enterococcus faecalis N06-0364 with low-level vancomycin resistance harboring a novel D-Ala-D-Ser gene cluster, vanL. Antimicrob Agents Chemother. 2008;52(7):2667-2672.
  • 27. Deshpande, L.M., Fritsche T.R., Moet G.J., Biedenbach D.J., Jones R.N. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007;58:163-170.
  • 28. Coombs G.W., Pearson J.C., Daly D.A., et al. Molecular epidemiology of enterococcal bacteremia in Australia. J Clin Microbiol. 2014;52:897-905.
  • 29. Eshaghi A., Shahinas D., Li A., et al. Characterization of an Enterococcus gallinarum Isolate Carrying a Dual vanA and vanB CassettE. J Clin Microbiol. 2015;53(7):2225-2229.
  • 30. Dekhnich А.V., Hachatryan N.N. New and old oxazolidinones: tedizolid vs. linezolid. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(2):121-129. Russian.
  • 31. Patel R., Gallagher J.C. Vancomycin-resistant enterococcal bacteremia pharmacotherapy. Ann Pharmacother. 2015;49(1):69-85.
  • 32. Mendes R.E., Hogan P.A., Streit J.M., Jones R.N., Flamm R.K. Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12). J Antimicrob Chemother. 2014;69(6):1582-1588.
  • 33. Pogue J.M., Paterson D.L., Pasculle A.W., Potoski B.A. Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant enterococcus. Infect Control Hosp Epidemiol. 2007;28(12):1382-1388.
  • 34. Aznar J., Lepe J.A., Dowzicky M.J. Antimicrobial susceptibility among E. faecalis and E. faecium from France, Germany, Italy, Spain and the UK (T.E.S.T. Surveillance Study, 2004-2009). J Chemother. 2012;24(2):74-80.
  • 35. Sader H.S., Farrell D.J., Flamm R.K., Jones R.N. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (20052012). Int J Antimicrob Agents. 2014;43(5):465-469.
  • 36. Casapao A.M., Kullar R., Davis S.L., et al. Multicenter study of highdose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother. 2013;57(9):4190-4196.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared